The basis for somatic gene therapy of cancer

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 2, 1996, Pages 73-83

  DeCruz, E E ^a   Walker, T L ^a   Dass, C R ^a   Burton, M A ^a  

^a CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Cancer gene therapy; Gene transfer; Liposomes; Tumor suppressor

Indexed keywords

ANIMAL; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENETICS; HUMAN; NEOPLASM; REVIEW;

ANIMALS; GENE THERAPY; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0030088959     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Vogelstein B, Kinzler KW. The multi-step nature of cancer. Trends in Genet 9: 138-141, 1993.
2. Weinberg RA. Tumor suppressor genes. Science 284: 1138-1146, 1991.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
4. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Eng J Med 329: 1318-1327, 1993.
5. Chambers AF. Mechanism of oncogene mediated alterations in metastatic ability. Biochem Cell Biol 70: 814-821, 1992.
6. Folkman J. The role of angiogenesis in tumor growth. Sem Cancer Biol 3: 65-71, 1992.
7. Porgador A, Feldman M, Eisenbach L. Immunotherapy of tumor metastasis via gene therapy. Natural Immunity 13: 113-130; 1994.
8. Bubenik J. Cytokine gene-modified vaccines for immunotherapy of cancer. Int J Oncol 6: 45-49, 1995.
9. Vieweg J, Boczkowski D, Roberson KM, et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic lipsomoes for gene therapy of human prostate cancer. Cancer Res 55: 2366-2372, 1995.
10. Vile RG, Hart IR. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann Oncol 5 (suppl 4): S59-S65, 1994.
11. Parmiani G, Colombo MP. Somatic gene therapy of human melanoma - preclinical studies and early clinical trials. Melanoma Res 5: 295-301, 1995.
12. Kerr JFR, Winterford CM, Harmon BV. Apoptosis - its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
13. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
14. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
15. Miller CW, et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50: 7950-7954, 1990.
16. Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Bocker W, Roessner A. Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Can Res & Clin Oncol 119: 172-178, 1993.
17. Reichel MB, Ohgaki H, Petersen I, Kleihues P. p53 mutations in primary human lung tumors and their metastases. Mol Carcinogen 9: 105-109, 1994.
18. Top B, Mooi WJ, Klaver SG, et al. Comparative analysis of p53 gene mutations and protein accumulation in human non-small lung cancer. Int J Cancer 64: 83-91, 1995.
19. Carder P. Wyllie AN, Purdie CA, Morris RG, White S, Piris J, Bird CC. Stablised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8: 1397-1401, 1993.
20. Stenmarkaskmalm M, et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Bur J Cancer 30A: 175-180, 1994.
21. Thor AD, Moore DH, Edgerton S, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-848, 1992.
22. Nigro JM, et al. Mutations in p53 gene occur in diverse human tumor types. Nature 342: 705-707, 1989.
23. Hollstein M, Sidransky D, Bogelstein B, Harris CC. p53 mutations in human cancers. Science 253: 49-53, 1991.
24. Albino AP, et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4: 35-45, 1994.
25. Boschman CR, Stryker S, Reddy JK, Rao MS. Expression of p53 protein in precursor lesions and adenocarcinoma of human adenocarcinoma of human pancreas. Am J Pathol 145: 1291-1295, 1994.
26. Soini, Y, Paakko P, Alavaikko M, Vahakangas K. p53 expression in lymphatic malignancies. J Clin Pathol 45: 1011-1014, 1992.
27. Mori N, Wada M, Yokota J, et al. Mutations of the p53 tumor suppressor gene in haematologic neoplasms. Br J Haematol 81: 235-238, 1992.
28. Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid malignancies of childhood. Blood 82: 3163-3169, 1993.
29. Frebourg T, Barbier N, Yan YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56: 608-615, 1995.
30. King P, Craft AW, Malcolm AJ. p53 expression in three separate tumors from a patient with Li Fraumeni's syndrome. J Clin Pathol 46: 676-677, 1993.
31. Birch JM, hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li Fraumeni families. Cancer Res 54: 1298-1304, 1994.
32. Donehower LA, Harvey M, Slagle BL, McArthur JJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 365: 215-221, 1992.
33. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA damaging agents. Oncogene 8: 307-318, 1993.
34. Kastan MB, Onyedkwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
35. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anti-cancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362, 1990.
36. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif 24: 203-214, 1991.
37. Lotem J, Sachs L. Regulation by bcl-2, c-muc and p53 susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentation-competent and -defective myeloid leukemic cells. Cell Growth Diff 4: 41-47, 1993.
38. Lowe SW, Ruley HE, Jacks T, Houseman DE. p53-dependent apoptosis modulates the cytoxicity of anticancer agents. Cell 74: 957-967, 1993.
39. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 84: 192-196, 1991.
40. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 protooncogenes. Nature 359: 554-556, 1992.
41. Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE. In vivo cisplatin chemotherapy selects for tumor cells with elevated c-myc expression. Br J Cancer 73: 610-614, 1996.
42. Davidoff AM, et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110: 259-264, 1991.
43. Sun XF, et al. Prognostic significance of cytopoasmic p53 oncoprotein in colorectral adenocarcinoma. Lancet 340: 1369-1373, 1992.
44. Horio Y, Takashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary re-sected non-small cell lung cancer. Cancer Res 53: 1-4, 1993.
45. E-Deiry X, et al. WAF1.CIP1 is ainduced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
46. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14: 1669-1679, 1994.
47. Hanson KD, Shichiri M, Follansbee MR, Sedivy JM. Effects of c-myc expression on cell cycle progression. Mol Cell Biol 14: 5748-5755, 1994.
48. Segawa K, Hokuto I, Minowa A, Ohyama K, Takano T. Cyclin E enhances p53-mediated transactivation. FEBS Letts 329: 283-286, 1993.
49. Chen CY, Olmer JD, Zhan Q, Fornace Jr AJ, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci (USA) 91: 2684-2688, 1994.
50. Zhan QM, El-Deiry W, Bae I, Alamo I, Kastan MB, Vogelstein B, Fornace AJ. Similarity of the DNA-damage reponsiveness and growth-suppression properties of WAF1/DIP1 and GADD45. Int J Oncol 6: 937-946, 1995.
51. Namba H, Hara T, Tukazaki T, et al. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/CIP1 pathway in human thyroid cells. Cancer Res 55: 2075-2080, 1995.
52. Serrano M, Hannon JH, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
53. Igaki H, et al. Mutation frequency of the P16/ CDKN2 gene in primary cancers in the digestive tract. Cancer Res 55: 3421-3423, 1995.
54. Igaki H, et al. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 203: 1090-1095, 1994.
55. Xu L, Sgroi D, Sterner CJ, et al. Mutational analysis of CDKN2 (NTS1/p16ink4) in human breast carcinomas. Cancer Res 54: 5262-5264, 1994.
56. Kamb A, et al. A cell-cycle regulator potentially involved in genesis of many tumor types. Science 264: 344-345, 1994.
57. INK4B) display frequent homozygous deletions in primary cells from T- but not B-cell lineage acute lymphoblastic leukaemia. Blood 84: 4038-4044, 1994.
58. Schmidt EE, Ichimura K, Reifenberger G, Colins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994.
59. Lydiatt WM, et al. Homozygous deletions and loss of expression of the CDKN2 gene occurs frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumours. Genes, Chromosomes & Cancer 13: 94-96, 1995.
60. Salmons B, Saller RM, Bauman JG, Gunzburg WH. Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia 9 (Suppl): S53-S60, 1995.
61. Brenner AJ, Aldaz CM. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and P16 inactivation in immortal breast epithelial cells. Cancer Res 55: 2892-2895, 1995.
62. Hoskins KF, Stropfer JE, Calzone KA, Merajver SD, Rebgeck TR, Barber JE, Weber BL. Assessment and counseling for women with a family history of breast cancer - a guide for clinicians. J Am Med Assoc 273: 577-585, 1995.
63. Szabo CL, King MC. Inherited breast and ovarian cancer. Hum Mol Genet 4: 1811-1817, 1995.
64. Kelsell DP, Black DM, Bishop DT, Spurr NK. Genetic analysis of the BRCA-1 region in a large breast/ovarian family: refinement of the minimal region. Hum Mol Genet 2: 1823-1828, 1993.
65. Lalle P, De Latour M, Rio P, Bignon YJ. Detection of allelic losses on 17q12-q21 chromosomal region in benign lesions and malignant tumours occurring in a familial context. Oncogene 9: 437-442, 1994.
66. Friedman LS, et al. Confirmation of BRCA1 by analysis of germline mutation linked to breast and ovarian cancer in ten families. Nature Genet 8: 437-442, 1994.
67. Narod SA, et al. A heterogeneity analysis of 145 breast-ovarian cancer families. Am J Hum Genet 56: 254-264, 1995.
68. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 72: 805-812, 1995.
69. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet 9: 444-450, 1995.
70. Wooster R, Neuhausen S, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265: 2088-2090, 1944.
71. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995.
72. George MJ. The present and future of haematopoietic cytokines in clinical practice. Stem Cells 12: 249-255, 1994.
73. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous drug delivery into adult mice. Science 261: 209-211, 1993.
74. Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice - involvement of scavenger receptors in its hepatic uptake. Pharm Res 12: 825-830, 1995.
75. Yang ZY, Laface D, Gromkowski SH, Nabel GJ, Namthorpe M, Norman J. Cancer gene therapy using plasmid DNA - pharmacokinetic study of DNA following injection in mice. Human Gene Therapy 6: 553-564, 1995.
76. Buttrick TM, Kass A, Kitsis RN, Kaplan ML, Leinwand LA. Behaviour of genes directly injected into the rat heart in vivo. Circ Res 70: 193-198, 1992.
77. Gal D, Weir L, Leclerc G, Pickering JG, Hogan J, Isner JM. Direct myocardial transfection in two animal models. Evaluation of parameters affecting gene expression and percutaneous gene delivery. Lab Invest 68: 18-25, 1993.
78. Wolff JA, Malone RW, Williams P, Chong W. Acsadi G, Jani A, Feigner PL. Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468, 1990.
79. Wolff JA, Williams P, Acsadi G, Jiao S, Jani A, Chong W. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 11: 474-485, 1991.
80. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1: 363-369, 1992.
81. Jiao S, Williams P, Berg RK, Hodgemean BA, Liu L, Repetto G, Wolff JA. Direct gene transfer into non-human primate myofibers in vivo. Hum Gene Ther 3: 21-33, 1992.
82. Hickman MA, Malone RW, Lehmannbruinsma K, Sih TR, Knoell D, Szoka FC, Walzern R, Carlson DM, Powell JS. Gene expression following direct injection of DNA into liver. Hum Gen Ther 5: 1477-1483, 1994.
83. Malone RW, Hickman MA, Lehmannbruinsma K, Sih TR, Walzem R, Carlson DM, Powell JS. Dexamethasone enhancement of gene expression after direct hepatic injection. J Biol Chem 269: 29903-29907, 1994.
84. Liu Y, Liggitt D, Zhong W, Tu GH, Gaensler K, Debs R. Cationic liposome-mediated intravenous gene delivery. J Biol Chem 270: 24864-24870, 1995.
85. Horn NA, Meek JA, Budahazi G, Marquet M. Cancer gene therapy using plasmid DNA - purification of DNA for human clinical trials. Hum Gene Ther 6: 565-573, 1995.
86. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retrovial wild-type p53 expression vector in an orthoptopic lung cancer model. J Natl Cancer Inst 86: 1458-1462, 1994.
87. Salmons B, Saller RM, Bauman JG, Gunzburg WH. Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia 9 (Suppl): S53-S60, 1995.
88. Julias JG, Hash D, Pathak VK. E(-) vectors - development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy. J Virol 69: 6839-6846, 1995.
89. Liu T-J, Zhang W-W, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of wild-type p53 gene via a recombinant adenovirus. Cancer Res 54: 3662-3666, 1994.
90. Willis KN, Maneval DC, Menzel P, et al. Development and characterisation of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5: 1079-1088, 1994.
91. Zhang WW, Fang XM, Mazur W, French BA, Georges RN, Roth JA. High efficiency gene transfer and high level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Therapy 1: 5-13, 1994.
92. Yang YP, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Medicine 1: 890-893, 1995.
93. Felgner JH, Kumar R, Sridhar CN, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269: 2550-2561, 1994.
94. Hofland H, Huang L. Inhibition of human ovarian carcinoma cell proliferation by liposome plasmid DNA complex. Biochem Biophys Res Comm 15: 492-496, 1995.
95. Brigham KL, et al. In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle. Am J Med Sci 298: 278-281, 1989.
96. Lesoonwood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson JA. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6: 395-405, 1995.
97. San H, Yang ZY, Pompili VJ, et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 4: 781-788, 1993.
98. Watanabe Y, Nomoto H, Takezawa R, Miyoshi N, Akaike T. Highly efficient transfection into primary cultured mouse hepatocytes by use of cation-liposomes - an application for immunization. J Biol Chem 116: 1220-1226, 1994.
99. Zabner J, Fasbender SJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270: 18997-19007, 1995.
100. Jones MN. Carbohydrate-mediated liposomal targeting and drug delivery. Adv Drug Del Rev 13: 215-249, 1994.
101. Holmberg EG, Reuer QR, Geisert EE, Owens JL. Delivery of plasmid DNA to glial cells using pH-sensitive immunoliposomes. Biochem Biophys Res Comm 201: 888-893, 1994.
102. Mori A, Huang L. Targeted immunoliposomes - potential role in the delivery of cytotoxic drugs. Clin Immunotherap 3: 227-240, 1995.
103. Park JW, Hong K, Carter P, et al. Development of anti-P185 (HER2) immunoliposomes for cancer therapy. Proc Natl Acad Sci (USA) 92: 1327-1331, 1995.
104. Jones MN, Hudson MJH. The targeting of immunoliposomes to tumor cells (A431) and the effects of encapsulated methotrexate. Biochewm Biophys Acta 1152: 231-242, 1993.
105. Moradpour D, Compagnon B, Wilson BE, Nicolau C, Wands JR. Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro. Hepatol 22: 1527-1537, 1995.
106. Suzuki S, Uno S, Fukuda Y, Aoki Y, Masuko T, Hashimoto Y. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br J Cancer 72: 663-668, 1995.
107. Nabel EG, Gordon D, Yang ZY, et al. Gene transfer In vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localisation. Hum Gene Ther 3: 649-656, 1992.
108. Parker SE, Vahlsing HL, Serfilippi LM, et al. Cancer gene therapy using plasmid DNA - safety evaluation in rodents and non-human primates. Hum Gene Ther 6: 575-590, 1995.
109. Napoli S, Burton MA, Martins IJ, Chem Y, Codde JP, Gray BN. Dose response and toxicity of doxorubicin microspheres in a rat tumor model. Anti-cancer Drugs 3: 47-53, 1992.
110. Codde JP, Lumsden AJ, Napoli S, Burton MA, Gray BN. A comparative study of the anticancer efficacy of doxorubicin-carrying microspheres and liposomes using a rat liver tumor model. Anti-cancer Res 13: 539-544, 1993.
111. Cortesi R, Esposito E, Menegatti E, Gambari R, Nastruzzi C. Gelatin microspheres as a new approach for the controlled delivery of synthetic oligonucleotides and PCR-generated DNA fragments. Int J Pharm 105: 181-186, 1994.
112. Alexis T, Boadi DK, QAuong D, Groboillot A, O'Neill L, Poncelot D, Neufeld RJ. Microencapsulation of DNA within alginate microspheres and cross-linked chitosin membranes for in vivo application. App Biochem Biotechnol 50: 93-106, 1995.